glp 1 agonist cardiovascular outcomes Bridging the gap between GLP1-receptor agonists and outcomes: evidence for the role of tirzepatide | Cardiovascular Diabetology Cardiovascular, mortality, and kidney outcomes
Description
See if you qualify
00203-5/asset/a0abd16a-3eaa-4d78-990d-ba94939c04c6/main.assets/gr2_lrg.jpg)
That best hormone

This article thoroughly traces the developmental milestones of GLP-1 drugs, from their initial discovery to their clinical application, detailing the evolution of diverse GLP-1 medications along with their distinct pharmacological properties

Limited head-to-head studies compare established glucagon-like peptide-1 receptor agonists (GLP-1 RAs), dipeptidyl peptidase-4 inhibitors (DPP-4is), and sodium-glucose co-transporter-2 inhibitors (SGLT-2is) to insulin in the management of uncontrolled type 2 diabetes mellitus (T2DM)
